New Double-Action drug enters human testing for Tough-to-Treat cancers
NCT ID NCT05357651
Summary
This is a first-in-human, early-stage study to check the safety and find the right dose of an experimental drug called LB1410. The drug is designed to help the immune system fight cancer by blocking two different targets (PD-1 and TIM-3) at once. It will be given by IV to about 100 adults with advanced solid tumors or lymphoma who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.